PreserFlo ® MicroShunt: An Overview of This Minimally Invasive Device for Open-Angle Glaucoma

For moderate-to-severe glaucoma, trabeculectomy remains the "gold standard" intraocular pressure (IOP)-lowering treatment; nonetheless, this method requires extensive post-operative maintenance. Microinvasive glaucoma surgery (MIGS) treatments are designed to lessen intra- and post-operati...

Full description

Saved in:
Bibliographic Details
Published in:Vision (Basel) 2022-02, Vol.6 (1), p.12
Main Authors: Gambini, Gloria, Carlà, Matteo Mario, Giannuzzi, Federico, Caporossi, Tomaso, De Vico, Umberto, Savastano, Alfonso, Baldascino, Antonio, Rizzo, Clara, Kilian, Raphael, Caporossi, Aldo, Rizzo, Stanislao
Format: Article
Language:English
Subjects:
Biocompatibility
Biodegradation
Biophysics
Clinical trials
Conjunctiva
Eye surgery
Feasibility studies
Glaucoma
glaucoma drainage devices
Medical research
micro-invasive glaucoma surgery
MicroShunt
Mitomycin C
Review
Safety
SIBS polymer
Styrene
Surgery
Surgical outcomes
Surgical techniques
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For moderate-to-severe glaucoma, trabeculectomy remains the "gold standard" intraocular pressure (IOP)-lowering treatment; nonetheless, this method requires extensive post-operative maintenance. Microinvasive glaucoma surgery (MIGS) treatments are designed to lessen intra- and post-operative care burden while offering an acceptable IOP decrease for individuals with mild to moderate glaucoma. The PreserFlo MicroShunt (previously InnFocus MicroShunt) is an 8.5 mm glaucoma drainage device manufactured from poly(styrene-block-isobutylene-block-styrene) (SIBS), an extremely biocompatible and bioinert material. The lumen is narrow enough to prevent hypotony, but big enough to avoid being obstructed by sloughed cells or pigment. The device is implanted ab externo, as a stand-alone procedure or in conjunction with cataract surgery, with intraoperative mitomycin C, and a bleb is produced under the conjunctiva and Tenon's capsule. The MicroShunt was CE-marked in 2012 and designed for primary open-angle glaucoma, the IOP of which remains uncontrolled after maximally tolerated topical treatment. Several clinical trials evaluating the MicroShunt's long-term safety and effectiveness have been conducted, highlighting the effectiveness of the device over time, along with a tolerable safety profile. The present review aims to gather evidence of PreserFlo's effectiveness and safety results almost 10 years after its introduction, and furthermore, to compare it with other MIGS and with the gold-standard trabeculectomy for glaucoma management.
ISSN:2411-5150
2411-5150
DOI:10.3390/vision6010012